Page last updated: 2024-11-03

4-aminobenzoic acid and Non-alcoholic Fatty Liver Disease

4-aminobenzoic acid has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

ExcerptRelevanceReference
"An orally bioavailable small molecule inhibitor of plasminogen activator inhibitor‑1 (PAI‑1) is currently being clinically assessed as a novel antithrombotic agent."1.56Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. ( Aihara, Y; Asada, K; Douhara, A; Kaji, K; Kawaratani, H; Kitade, M; Miyata, T; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Takaya, H; Yoshiji, H, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Noguchi, R1
Kaji, K1
Namisaki, T1
Moriya, K1
Kawaratani, H1
Kitade, M1
Takaya, H1
Aihara, Y1
Douhara, A1
Asada, K1
Nishimura, N1
Miyata, T1
Yoshiji, H1

Other Studies

1 other study available for 4-aminobenzoic acid and Non-alcoholic Fatty Liver Disease

ArticleYear
Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats.
    Molecular medicine reports, 2020, Volume: 22, Issue:4

    Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fibrinol

2020